Overnight thalamic TES-TI to modulate sleep spindles in schizophrenia and matched healthy controls
Official title: A Pilot Feasibility Study of Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls
Run by University of Wisconsin, Madison · NCT07680114 · Data updated 2026-11-12
This study tests whether a noninvasive brain stimulation method during sleep can change sleep spindles in people with schizophrenia spectrum disorders and in healthy adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | October 2026 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | October 1, 2026 |
| Trial ID | NCT07680114 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with schizophrenia spectrum disorders or healthy controls matched by age and sex, with MRI suitability and stable clinical status.
✕Probably not a fit
Patients not showing spindle modulation or not meeting sleep or imaging eligibility may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-site, single-blind, proof-of-concept study using transcranial electrical stimulation with temporal interference (TES-TI) during overnight sleep. Electrodes are placed using an MRI-guided personalized montage to target the thalamus while participants sleep, and brain activity is recorded with high-density EEG and standard sleep sensors. Each participant undergoes two overnight sessions: a baseline night with sham stimulation and a stimulation night, separated by at least two weeks. Primary outcomes look at spindle-frequency activity during stable N2 sleep, with exploratory analyses comparing baseline deficits and responsiveness across groups and linking changes to cognitive performance.
Why it matters
Potential benefit: If successful, TES-TI could provide a noninvasive way to influence sleep-related brain activity in schizophrenia.
How similar studies have gone: Prior noninvasive brain stimulation studies have shown feasibility in modulating sleep-related brain activity, but this specific TES-TI approach is exploratory and novel in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (all participants): * U.S. citizen or holding permanent resident status * English-speaking Inclusion Criteria (Participants with SSD): * DSM-5 schizophrenia spectrum disorder (SSD) diagnosis, defined as schizophrenia, schizoaffective disorder, or schizophreniform disorder (confirmed by clinical interview and/or chart review) * Chronic illness, defined as diagnosis of SSD for at least 1 year * Clinically stable outpatient (no psychiatric hospitalization in past 6 months; no change in antipsychotic medication in the past 6 weeks) Inclusion Criteria (Healthy Controls): * Medically healthy (based on self-report and study team review) * Matched to SSD participants on age (±5 years) and sex Exclusion Criteria (all participants): * Current or past history of clinically significant neurological disorder or acquired neurological disease (e.g., stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified on the structural MRI) * Active suicidal ideation, plan, or intent (assessed via PHQ-9 item 9 and follow-up Columbia-Suicide Severity Rating Scale (C-SSRS) Screener; see Safety Response Procedure) * Inability to provide informed consent, including inadequate decisional capacity in the judgment of the study team and/or study psychiatrist * History of head trauma resulting in prolonged loss of consciousness; or a history of \>3 grade I concussions * Current poorly controlled headaches, including intractable or frequent migraines * Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist * Possible pregnancy or plan to become pregnant in the next 6 months (self reported) * Any metal in the head * Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator) * Dental implants * Permanent retainers * Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions * Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions * Current use of medications known to substantially lower seizure threshold, specifically chlorpromazine, clozapine, bupropion, clomipramine, or maprotiline; or other medications at doses known to substantially lower seizure threshold in the judgment of the PI or Study Psychiatrist * Current use of medications known to directly and substantially enhance sleep spindle activity, including benzodiazepines; non-benzodiazepine "Z-drug" hypnotics (zolpidem, eszopiclone, zaleplon); barbiturates; and gabapentin or pregabalin, within 2 weeks of the overnight study visits. Other sedating medications used as sleep aids (e.g., trazodone, hydroxyzine, mirtazapine) are permitted provided the regimen is stable across the two overnight visits; dose and timing will be recorded as covariates * Current moderate-to-severe alcohol or other substance use disorder (DSM-5) other than nicotine or caffeine * Active scalp lesions, broken skin, or skin conditions at planned electrode sites that would preclude safe electrode application * Claustrophobia (a fear of small or closed places) * Back problems that would prevent lying flat for up to two hours * Regular night-shift work (second or third shift) * Sleep apnea or other sleep disorder (self-reported) Exclusion Criteria (Healthy Controls): * Self-reported history of inpatient psychiatric hospitalization * Self-reported current or past diagnosis of schizophrenia or any other psychotic disorder * Self-reported first-degree relative with schizophrenia or any other psychotic disorder * Self-reported current or past diagnosis of bipolar disorder or major depressive disorder with psychotic features, or current treatment for any psychiatric disorder other than depression or anxiety (handled via the medication rule below) * Current use of any psychotropic medication, with the exception of a single SSRI or SNRI taken at a stable dose for at least 6 weeks for depression or anxiety. Current use of antipsychotics, tricyclic antidepressants, mirtazapine, trazodone, lithium or other mood stabilizers, benzodiazepines, non-benzodiazepine hypnotics, other anxiolytics, or stimulants will result in exclusion.
Where it's running
-
University of Wisconsin
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Larissa Albantakis, PhD — University of Wisconsin, Madison
- Study coordinator: ONSETS Study
- Email: onsets@psychiatry.wisc.edu
- Phone: 608-263-4313
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Lumateperone to improve motivation in patients with schizophrenia and psychosis
This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
XEP527 in stable schizophrenia: safety and how it behaves in the body
This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.
-
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.
-
Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder
This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.
-
Neuronavigated rTMS for treatment-resistant auditory hallucinations
We are testing whether personalized neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations in adults who don’t respond to medication.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.